Passage No. | WJ379 | EC50 | Mutation | BC035 | EC50 | Mutation | Ama | EC50a |
---|---|---|---|---|---|---|---|---|
µM | µM | µM | µM | µM | µM | |||
0 | 0.49 | N31 | 2.2 | N31 | 0.26 | |||
1 | 0.30 | 0.33 | N.T. | 2.0 | 1.2 | N.T. | 0.20 | Resb |
2 | 0.60 | 0.38 | N.T. | 4.0 | 2.6 | N.T. | Not continued after passage 1 due to significant resistance | |
3 | 1.20 | 1.6 | No mutation | 8.0 | 7.2 | No mutation | ||
4 | 2.50 | 35.9 | L26I | 16.0 | 25.3 | N31D/I32T | ||
5 | 5.0 | 28.0 | L26I | 16.0 | 27.3 | N31D/I32T | ||
6 | 5.0 | 15.5 | N31S/L26I | 16.0 | N.T. | N31D/I32T | ||
7 | 0 | N.T. | N.T. | 0 | N.T. | N.T. | ||
8 | 0 | >30 | N.T. | 0 | 20.0 | N.T. | ||
9 | 0 | >30 | L26I (100%) | 0 | 22.7 | I32T (100%) | ||
10 | 0 | N.T. | N.T. | 0 | N.T. | N.T. | ||
11 | 0 | >30 | N.T. | 0 | >20 | N.T. |
Ama, amantadine; Res, rimantadine; N.T., not tested.
↵a A/WSN/33 M2 N31S virus was used.
↵b Complete resistant viruses were selected as shown by the plaque-reduction assays. No complete plaque inhibition was observed even when amantadine was added at 30 µM (30% of plaque remained compared with no drug control).